Ischemix Elects Peter G. Milner, MD To Board Of Directors

MAYNARD, Mass.--(BUSINESS WIRE)--Ischemix, Inc., a clinical-stage pharmaceutical company focused on hospital-acquired kidney and cardiac injury, announced today that Peter G. Milner, MD has been elected to its Board of Directors. David A. DeWahl, Jr., President and CEO of Ischemix said "Dr. Milner's breadth of experience in pharmaceutical development and regulatory approvals will enhance the progress of our leading drug candidate and pipeline toward regulatory and clinical acceptance. His participation on our Board is a real vote of confidence in our drug candidates and approach."